Permanent alopecia after haematopoietic stem cell transplantation (HSCT) is distressing and few studies have investigated this late effect. The aim of the study was to assess the percentage of patients with alopecia and investigate risk factors for alopecia. Patients who underwent allogeneic HSCT before age 19 years, from January 1990 to January 2013, who were at least 2 years after transplant and in follow-up in our clinic were included. Alopecia was defined as clinically apparent decreased hair density. Possible risk factors considered for alopecia after HSCT included: gender, age, diagnosis, donor type, conditioning regimen: cranial irradiation (TBI/cranial radiotherapy) and/or chemotherapy, which chemotherapeutic agents were used and acute/chronic GvHD. The percentage of permanent alopecia in our cohort was 15.6% (41/263 patients). All patients had diffuse alopecia except for one with alopecia totalis. In multivariate analysis, a conditioning regimen with busulphan and busulphan plus fludarabine (odds ratio (OR) 5.7 (confidence interval (CI): 2.5-12.7) and OR 7.4 (CI: 3.3-16.2), respectively, was the main risk factor and associated with alopecia independent of acute/chronic GvHD. Neither TBI nor other alkylating chemotherapy, including treosulfan, was associated with alopecia. In conclusion, permanent alopecia after HSCT is associated with busulphan and GvHD and occurs in 16% of patients. INTRODUCTION Allogeneic haematopoietic stem cell transplantation (HSCT) is a well-established treatment for a wide spectrum of diseases including malignant and nonmalignant haematological diseases, immunodeficiencies and other inborn errors of metabolism. Survival after HSCT has improved considerably over the years with better supportive care and HLA matching, but this cure comes at a price and survival is still associated with late effects of this intensive treatment. Many studies have been published on the late effects after HSCT in childhood 1-5 and the main late effects described in these studies include endocrine problems, pulmonary toxicity and secondary malignancy.
INTRODUCTION
Allogeneic haematopoietic stem cell transplantation (HSCT) is a well-established treatment for a wide spectrum of diseases including malignant and nonmalignant haematological diseases, immunodeficiencies and other inborn errors of metabolism. Survival after HSCT has improved considerably over the years with better supportive care and HLA matching, but this cure comes at a price and survival is still associated with late effects of this intensive treatment. Many studies have been published on the late effects after HSCT in childhood [1] [2] [3] [4] [5] and the main late effects described in these studies include endocrine problems, pulmonary toxicity and secondary malignancy.
Only a few studies have assessed late effects after HSCT concerning hair and skin problems, apart from the well-described manifestations of chronic GvHD of the skin. Reversible alopecia is a commonly observed, important and distressing side effect of chemotherapy and especially after high-dose chemotherapy with alkylating agents as is used in the setting of HSCT. Permanent alopecia after chemotherapy and/or radiotherapy however is rarer, but has been described in several studies. [6] [7] [8] [9] [10] [11] Some studies have described permanent alopecia after allogeneic HSCT, but most of these studies are based on small patient numbers or case reports only. [12] [13] [14] [15] The prevalence of permanent alopecia after HSCT in these studies varies between 0.9 and 71%. 6, 12, 13, 16, 17 To our knowledge, only two studies on permanent alopecia after HSCT in childhood have been published by Kinahan et al . that showed a prevalence of 14%. 7, 8 Permanent, usually diffuse, alopecia is a severe late effect for the patients as well as their parents and is associated with psychosocial distress. This severe problem warrants more attention and research into the options for prevention and/or treatment. In recent years, we noticed that many children in our centre developed permanent alopecia after HSCT, and as such we investigated the percentage of alopecia among the patients seen in our late effects clinic in recent years and the risk factors for permanent alopecia.
PATIENTS AND METHODS
This cross-sectional single-centre study was performed at the Paediatric Hematopoietic Stem Cell Transplantation (SCT) Unit of the Leiden University Medical Centre. Inclusion criteria for this study were: (1) allogeneic HSCT performed before age 19 years from 1 January 1990 to 1 January 2013, (2) alive at least 2 years after HSCT (to assess permanence of alopecia) and (3) assessed for alopecia in our late effects clinic after 1 January 2010. In the absence of a uniform, internationally standardized method for the classification of chemotherapy-induced alopecia, we defined alopecia as clinically apparent decreased hair density of the scalp (diffuse alopecia or alopecia totalis) as assessed by a paediatrician specialized in post transplant care. In none of our patients was alopecia areata or androgenic alopecia clinically suspected and no signs of inflammation/ infection were found. In addition, thyroid function was normal in all patients.
Diagnosis
Patients received HSCT for various malignant and nonmalignant diseases. Indications for HSCT were divided into three disease groups: immunodeficiency and other inborn errors of metabolism, benign haematological diseases and malignant haematological diseases. 1 
Conditioning regimens
Conditioning regimens varied according to indication for HSCT and in time. Thirty different conditioning regimens were used in our patients and the regimens used in at least 10 patients are shown in Table 1 . One patient received conditioning with serotherapy only, but no chemotherapy. TBI was given unfractionated (5-7.5 Gy in 1 dose or 12 Gy in 2 doses, depending on age) in 56 patients, and fractionated (12 Gy in 6 fractions) in 15 patients. Two patients received cranial radiotherapy 3 × 2 Gy in addition to TBI. TLI was also applied in 16 patients in doses of 4 or 5 Gy.
Conditioning regimens were categorized into two groups: with or without irradiation to the head, including TBI and cranial radiotherapy. Within the group of patients conditioned without irradiation to the head, the chemotherapeutic agents used in the conditioning regimen were assessed.
Busulphan was in earlier years given at a fixed dose, whether orally or IV (since 2000), but since 2004 therapeutic drug monitoring for busulphan was introduced and aimed at a high area under the curve (AUC 80-90 μg/ L × h) in most patients and a low AUC (60-70 μg/L × h) in the rest. AUC was available in 51 of 126 busulphan-treated patients.
Risk factors for permanent alopecia
Possible risk factors considered for alopecia included: gender, age, diagnosis (3 groups), donor type and conditioning regimen. A conditioning regimen with TBI/cranial radiotherapy versus a conditioning regimen without irradiation to the head was compared. Within the chemotherapy only group, a regimen with or without busulphan, cyclophosphamide, thiotepa, treosulfan and fludarabine, and combinations of busulphan plus cyclophosphamide and busulphan plus fludarabine was compared. In addition, a history of acute GvHD and/or chronic GvHD was assessed as a risk factor for alopecia. Acute GvHD was defined as present or absent independent of organ involvement (skin, gastrointestinal and/or liver). Chronic GvHD was both assessed irrespective of organ involvement, but also for skin, especially sclerodermatous GvHD, separately.
Statistical analysis
The percentage of patients with permanent alopecia after HSCT was assessed. Pearson's χ 2 test for noncontinuous variables and Mann-Whitney U-test for age were used to compare patient characteristics between the two groups (with/without alopecia). Six different logistic regression models were used to assess the effect of (1) busulphan, (2) busulphan plus fludarabine, (3) busulphan together with acute GvHD or (4) with chronic GvHD, (5) busulphan plus fludarabine with acute GvHD or (6) with chronic GvHD on alopecia. Logistic regression was done with age at HSCT and gender as adjusting variables. All statistical analyses were performed with ISB SPSS Statistics, version 23.0 (IBM, Corp, Armonk, NY, USA). A P-value of o0.05 was considered statistically significant.
RESULTS

Patient characteristics and percentage of permanent alopecia
A total of 263 patients, who survived at least 2 years after HSCT, were seen in our late effects clinic in recent years (after 1 January 2010) and could be assessed for alopecia. Permanent alopecia in our cohort was found in 15.6% (41/263) of the patients. In 40 patients, alopecia was diffuse, with sparse and often also thin and brittle hair ( Figure 1 ). One female patient had alopecia totalis with only a few nonpigmented brittle hairs (vellus hair) on the scalp. All patients with alopecia had normal eyebrows and eyelashes, and in older children, in whom this could be assessed, normal body hair distribution. The clinical characteristics of patients with and without alopecia are shown in Table 2 .
Risk factors for permanent alopecia No difference was found regarding gender, age at HSCT, diagnosis group, donor type and conditioning regimen with or without irradiation to the head. However, among children conditioned without irradiation to the head, significantly more children conditioned with busulphan, either with or without fludarabine, developed permanent alopecia, whereas none of the patients treated with treosulfan, but not busulphan, developed permanent alopecia (Table 2) . After a conditioning regimen including busulphan, 30/126 (23.8%) developed permanent alopecia as compared with 23/177 (13%) and 4/30 (13.3%) in patients conditioned with cyclophosphamide or thiotepa, respectively. Figure 1 . Diffuse alopecia in two children post HSCT, both after a conditioning regimen including busulphan.
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In 51 patients, AUC of busulphan was known and was compared in patients with or without alopecia. Four of 15 (27%) patients with a busulphan AUC o75 mg × h/L as compared with 14 of 36 (39%) patients with an AUC 475 had permanent alopecia. Results were not significantly different (P = 0.19).
Of the 20 patients who received a second transplant, and thus were conditioned twice, none developed alopecia.
Both a history of acute GVHD and of chronic GVHD was more common in patients with permanent alopecia (P = 0.001 and P = 0.002, respectively, Table 2 ). The severity grading of acute GvHD was not associated with the presence of alopecia (P = 0.317; results not shown). Among patients who had chronic GvHD, 6 of 23 patients with skin involvement as compared with 6 of 14 patients without skin involvement (4 bronchiolitis obliterans, 1 ocular and 1 gastrointestinal chronic GvHD) had permanent alopecia.
Several multivariate logistic regression models have been estimated. The effects of busulphan and busulphan plus fludarabine, acute GvHD and chronic GvHD, adjusted for age at HSCT and gender, have been investigated. Results are shown in Table 3 . Busulphan and busulphan plus fludarabine were significantly associated with alopecia (odds ratio (OR) 5.7 (95% confidence interval (CI): 2.5-12.7) and OR 7.4 (CI: 3.3-16.2), respectively).
DISCUSSION
Permanent alopecia has been defined as alopecia persisting for 46 months to 1 year after chemotherapy or radiotherapy. 19, 20 In this study, patients were assessed 42 years after HSCT and 16% of children were diagnosed with permanent alopecia. All patients with alopecia had normal eyebrows and eyelashes. Body hair can only be assessed after puberty and is even then difficult to assess because of the current trend for depilation of body hair, but was present in those patients in whom this could be assessed. This is in accordance with previous reports in most patients with permanent alopecia, 6,12,13 although several studies described some patients with additional loss of facial and/or body hair. 11, 13, 21 Alopecia generally refers to a lower density of hair follicles per area of skin, but no uniform definition of alopecia exists. The severity of alopecia can be graded according to several scales, as reviewed by Yeager and Olsen. 22 According to the World Health Organization (WHO) and Common Terminology Criteria for Adverse Events version 4.0 (CTCAE V4.0) classification, our patients mostly had grade 2, moderate, patchy hair loss and grade 1, o50% hair loss, respectively. No biopsies were performed in our patients, because we felt this was too invasive a procedure in children. The clinical impression was of a nonscarring and uninflamed scalp with a reduced number of hair follicles. Pathological examination of biopsies performed in patients with permanent alopecia in other studies showed a decreased number of hair follicles and hair follicle destruction with an increase in vellus hair formation and absence of inflammation or fibrosis. 9, 11, 14, 15, 21 Permanent alopecia is thought to be due to destruction of hair follicle stem cells. 20, 23 Compared with their differentiated progeny of the hair matrix, hair follicle stem cells of the bulge area have a low proliferation rate and are generally less sensitive to chemotherapy and radiotherapy used in the treatment of cancer and in conditioning for HSCT. 23 Our study showed that busulphan was the main risk factor for permanent alopecia as has been described by others. [12] [13] [14] 16, 17, 19, 21, 24 Other drugs, especially alkylating agents in the setting of HSCT, have been implicated in causing permanent alopecia as well. 6, 18 We did not find an association with the other alkylating agents applied in our patients, including cyclophosphamide, thiotepa and melphalan. None of the patients treated with treosulfan, which has replaced busulphan in some of the conditioning regimens in our centre, developed permanent alopecia. The use of treosulfan instead of busulphan in conditioning regimens has been shown to be associated with less acute toxicity, such as pulmonary and liver toxicity, and possibly also with reduced long-term toxicity, as has been suggested for infertility. Our study suggests that replacing busulphan by treosulfan in the conditioning regimen can also reduce the risk for permanent alopecia. The mechanism by which busulphan is associated with a higher risk of permanent alopecia as compared with other alkylating agents is unknown. Busulphan is a lipophilic drug with low water solubility as compared with other alkylating agents, and especially treosulfan that shows high water solubility. It could thus be hypothesized that busulphan persists in the hair follicles for a longer time with a higher risk of apoptosis of follicle stem cells. The combination of busulphan and fludarabine was also associated with alopecia, whereas the combination of busulphan with cyclophosphamide was not. Replacing cyclophosphamide by fludarabine coincided with the start of therapeutic drug monitoring for busulphan with a high AUC target in most patients. We thus hypothesized that the toxicity of busulphan combined with fludarabine on hair follicles could be due either to a potentiating effect of fludarabine on busulphan, as has been described for the cytotoxicity of this combination together with clofarabine in leukemia treatment, 25 or to higher exposure to busulphan. However, no difference in AUC of busulphan was found when patients with and without alopecia were compared, although the number of patients with known AUC was small.
Irradiation to the head as applied with TBI was not associated with an increased risk of permanent alopecia. This is in accordance with other studies that compared a busulphan-based conditioning regimen with TBI and found busulphan as the major risk factor for permanent alopecia. 17, 24 Permanent alopecia has been described after cranial radiotherapy for central nervous system tumours where much higher doses of irradiation are applied. 8, 10 The lethal dose for the hair follicle stem cell has been estimated to be 16 Gy, 26 and TBI doses given to our patients were substantially below this dose. Only two patients received an additional cranial boost with a total dose on the head of 18 Gy, but did not develop permanent alopecia.
Although in the literature both older age and younger age at the time of exposure to chemotherapy have been described as risk factors for alopecia, 8, 18 in our study median age at HSCT was not different for patients with or without alopecia.
Both acute and chronic GvHD were associated with permanent alopecia. The OR for busulphan with or without fludarabine did not change when a multivariate logistic regression model with GvHD (either acute or chronic) was estimated, suggesting that busulphan conditioning independently confers a risk of alopecia. Alopecia is a well-known problem in patients with chronic GvHD of the skin and can manifest as diffuse alopecia with fibrosis and scarring of the scalp skin. 27 In addition, patients with chronic GvHD are more likely to develop alopecia areata. To our surprise, although numbers were small, alopecia was associated with chronic GvHD irrespective of whether the skin was a target organ for chronic GvHD.
In our experience, alopecia was considered to be a major problem for both the patients and their parents. They felt exposed to scrutiny by other people because of their appearance and their alopecia was a constant reminder and visible sign of the disease and treatment they had gone through. Most of these patients were referred to the dermatologist, but treatment options are limited and none were applied in our patients. Minoxidil, which can be applied in androgenic baldness, has been tried in chemotherapy-induced alopecia but with limited success. Hair extensions can be applied if the structure of the hair is normal, and in alopecia totalis a wig or head cover is the only possibility to improve appearance. In our patients, hair extensions were applied in one girl and the female patient with alopecia totalis wears a wig. Maybe in some cases improvement could be achieved with hair transplantation, but options are limited as the alopecia characteristically affects the entire scalp. Regarding prevention of hair loss at the time of the insult, many drugs have been tried with various successes and scalp cooling may be applied. However, scalp cooling may not be tolerated by children. An excellent overview of the agents that have been used for prevention and treatment of chemotherapy induced alopecia is given in the paper by Yeager and Olsen. 22 As permanent alopecia after HSCT in childhood is found to be a common occurrence, it is crucial that patients and/or their parents be informed of this risk before transplant. Clinicians should be cautious when providing patients with absolute reassurance that their hair will regrow following HSCT, as our study demonstrates that this may not be the case for all children.
This study has several limitations. As no internationally accepted strict definition for alopecia (hair follicle density, hair shaft diameter) exists, the diagnosis of alopecia was made by clinical assessment. Although most patients or parents noticed alopecia and brought it to our attention themselves, we might have missed some patients with mild alopecia. On the other hand, some patients who came to transplant without scalp hair due to pretransplant chemotherapy might have had genetically thin and sparse hair that we were not aware of. Analysis of the drugs associated with alopecia was hampered by the fact that over time many different conditioning regimens with different combinations of drugs were applied. For most of these drugs serum levels and thus actual exposure was unknown. In the near future, more data on busulphan exposure will become available and allow analysis of a possible dose relationship with alopecia.
In conclusion, permanent alopecia after HSCT in childhood is a common and distressing late effect that warrants further study into risk factors, prevention and treatment. We hope that our study will increase awareness of this significant patient issue.
